"At the end of the harvest season in Brazil, regular
stock-taking revealed an unexpectedly high channel inventory
level of crop protection products," the company said in an
unscheduled statement.
This would result in a one-time hit of 300-400 million euros
($342-$456 million) on full-year earnings before interest,
taxes, depreciation and amortisation (EBITDA).
Bayer, in the midst of seeking regulatory approval for its $66
billion takeover of U.S. seeds group Monsanto <MON.N>, said it
would adjust its business outlook when it publishes second
quarter results, due on July 27, without providing details.
The shares were down 4.3 percent to 113 euros at 0758 GMT.
The company also cited unfavorable currency developments but
added its pharmaceuticals division and chemicals business
Covestro <1COV.DE> were still performing strongly, while
business at its animal health unit was line with expectations.
Bayer has been trying to overcome a weaker than expected
performance of key consumer care brands Coppertone sun screen
and Dr. Scholl's foot care products, acquired from Merck & Co <MRK.N>.
When asked about Bayer's plan to file for regulatory approval in
Europe for the Monsanto deal this quarter, a spokesman said that
remarks by Bayer CEO Werner Baumann last week, reaffirming that
goal, were still valid.
(Reporting by Ludwig Burger; Editing by Harro ten Wolde and Mark
Potter)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|